Diffuse Parenchymal Lung Disease Clinical Trial
Official title:
Ultra-Low Dose Computed Tomography For Diagnosis And Follow-Up Of Patients With Diffuse Parenchymal Lung Disease (DPLD)
The primary intention of this study is to determine the diagnostic performance of ultra-low-dose CT (ULDCT) in diagnosis and follow-up of diffuse parenchymal lung disease (DPLD). We hypothesize that inspiratory and expiratory chest ULDCT has comparable diagnostic yield to standard dose chest High-resolution computed tomography (HRCT) and utility for follow-up of patients with known DPLD. We will study this hypothesis through the following aims: 1. Determine whether inspiratory and expiratory ULDCT are comparable to HRCT in identifying mosaic attenuation due to air-trapping. 2. Determine whether ULDCT is as good as HRCT for follow-up of patients with established DPLD to identify disease progression.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | January 30, 2024 |
Est. primary completion date | January 30, 2024 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: 1. suspected or known DPLD 2. referred to DPLD observation Exclusion Criteria: 1. other lung related diseases - |
Country | Name | City | State |
---|---|---|---|
Israel | Sheba Medical Center | Ramat Gan |
Lead Sponsor | Collaborator |
---|---|
Sheba Medical Center |
Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary outcome measure of this study is to determine the diagnostic performance of ULDCT in diagnosis of DPLD. | The diagnostic performance will be evaluated according to the biopsy results | during the procedure/surgery | |
Primary | The primary outcome measure of this study is to determine the prognostic performance of ULDCT in the follow up of DPLD. | The diagnostic performance will be evaluated according to the biopsy results | during the procedure/surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01462006 -
Double-blind Placebo-controlled Pilot Study of Sirolimus in Idiopathic Pulmonary Fibrosis (IPF)
|
N/A | |
Completed |
NCT01948518 -
Effect of Sildenafil on Diffusion Capacity in Patients With PH and Parenchymal Lung Disease
|
N/A | |
Completed |
NCT00453713 -
Race, Ethnicity, and Diffuse Parenchymal Lung Disease
|
N/A | |
Active, not recruiting |
NCT03101397 -
The Clinical Value of Serum KL-6 Changes on Evaluating Disease Development in Different Diffuse Parenchymal Lung Disease
|
N/A | |
Not yet recruiting |
NCT06171425 -
Evaluation of Patients With Diffuse Parenchymal Lung Diseases Regarding Frailty
|
||
Suspended |
NCT02615938 -
Hydroxychloroquin (HCQ) in Pediatric Interstitial Lung Disease (ILD)
|
Phase 2 |